SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

30 May 2022 Evaluate
The sales for the March 2022 quarter moved down -64.43% to Rs. 609.19 millions as compared to Rs. 1712.87 millions during the year ago period.Profit after Tax for the quarter ended March 2022 saw a decline of -59.22% from Rs. 222.13 millions to Rs. 90.59  millions.Operating profit Margin for the quarter ended March 2022 slipped to -38.61% as compared to 423.97% of corresponding quarter ended March 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 609.19 1712.87 -64.43 5198.74 5631.78 -7.69 5198.74 5631.78 -7.69
Other Income 4.26 13.03 -67.31 51.98 34.53 50.54 51.98 34.53 50.54
PBIDT -38.61 423.97 -109.11 1196.83 1245.63 -3.92 1196.83 1245.63 -3.92
Interest 43.41 25.48 70.37 188.75 111.62 69.10 188.75 111.62 69.10
PBDT -82.02 398.49 -120.58 1008.08 1134.01 -11.10 1008.08 1134.01 -11.10
Depreciation 79.72 55.41 43.87 321.52 222.82 44.30 321.52 222.82 44.30
PBT -161.74 343.08 -147.14 686.56 911.19 -24.65 686.56 911.19 -24.65
TAX -252.33 120.95 -308.62 6.18 301.55 -97.95 6.18 301.55 -97.95
Deferred Tax -221.54 65.49 -438.28 -143.02 141.09 -201.37 -143.02 141.09 -201.37
PAT 90.59 222.13 -59.22 680.38 609.64 11.60 680.38 609.64 11.60
Equity 84.65 84.65 0.00 84.65 84.65 0.00 84.65 84.65 0.00
PBIDTM(%) -6.34 24.75 -125.61 23.02 22.12 4.09 23.02 22.12 4.09

SMS Pharmaceuticals Share Price

414.90 -5.70 (-1.36%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×